📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. (2021)

First Author: Verstovsek S

Attributed to: Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2217/fon-2020-1048

PubMed Identifier: 33423550

Publication URI: http://europepmc.org/abstract/MED/33423550

Type: Journal Article/Review

Volume: 17

Parent Publication: Future oncology (London, England)

Issue: 12

ISSN: 1479-6694